Alpine Immune Sciences Announces Poster Presentation at 2020 Crohn’s & Colitis Congress

January 6, 2020

SEATTLE--(BUSINESS WIRE)--Jan. 6, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohn’s & Colitis Congress taking place January 23-25, 2020, in Austin, Texas.

Details of the presentation are as follows:

  • Presentation Title: ALPN-101, A First-In-Class Dual ICOS/CD28 Antagonist, Demonstrates Efficacy in Patient-Derived PBMC In Vitro and in an In Vivo T Cell Transfer Model of Chronic Inflammatory Bowel Disease (IBD)
  • Session Title: Animal Models: Pre-Clinical Treatment of Intestinal Inflammation
  • Dates and Times: Thursday, January 23, 2020, 7:00 – 9:00 p.m. and Friday, January 24, 2020, 3:50 – 4:20 p.m.
  • Presentation Location: Exhibit Hall 1, Austin Convention Center
  • Session Type: Poster Session
  • Poster Number: P156

An abstract of the presentation is available in the online planner section of the Crohn’s & Colitis Congress website and in the Congress Mobile App.

About ALPN-101

ALPN-101 is a novel Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD™), and a first-in-class therapeutic designed to inhibit simultaneously the CD28 and ICOS inflammation pathways. CD28 and ICOS are closely-related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases. In preclinical models of graft versus host disease, inflammatory arthritis, connective tissue disease, and multiple sclerosis, ALPN-101 demonstrates efficacy superior to agents blocking the CD28 – CD80/86 or ICOS - ICOSL pathways alone.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients’ lives via unique protein engineering technologies. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a selective dual T cell costimulation blocker engineered to reduce pathogenic T and B cell immune responses by blocking ICOS and CD28. ALPN-101 has recently completed enrollment in a Phase 1 healthy volunteer trial. The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit

Source: Alpine Immune Sciences, Inc.

Investor Relations:
Pure Communications
Courtney Dugan, 212-257-6723
[email protected]

Media Relations:
Pure Communications
Sheryl Seapy, 213-262-9390
[email protected]